AI Insight: Cytek Biosciences trades 30.9% above its high-confidence fair value of $3.19, indicating potential overvaluation. Monte Carlo analysis shows substantial downside risk with 100% scenarios below the current price and median value at $0.50, highlighting volatility and weak profitability metrics. Liquidity and leverage scores are strong, but profitability and efficiency remain critical concerns.